Health Catalyst reported Q3 2026 revenue exceeding guidance, driven by a significant gain from the sale of its Vitalware business. While net income was strong due to this one-time event, adjusted results show an underlying loss and year-over-year revenue declines, indicating mixed operational performance.
Health Catalyst announced Q3 2026 results, reporting revenue of $56.3 million, which surpassed their guidance. The headline net income of $40.5 million, or $0.53 per share, was significantly boosted by a $65.9 million gain from the sale of its Vitalware business. However, adjusted for one-time items, the company reported a loss of $0.03 per share, indicating that operational profitability was not as strong as the headline figure suggests. Management reaffirmed full-year guidance, which could be seen as a positive for stability but also implies no significant upside surprise from the core business. The year-over-year revenue decline, attributed to the Vitalware divestiture and platform migration challenges, highlights ongoing operational hurdles. For traders, the short-term impact might be neutral to slightly positive due to the revenue beat, but the underlying adjusted loss and revenue declines present a long-term risk regarding core business growth and profitability once the one-time gain is excluded.